Potential beneficial effects of low molecular weight heparin on cognitive impairment in elderly patients on haemodialysis

Drugs and Aging

Volumn 29, Issue 1, 2012, Pages 1-7

  Sain, Milenka ^a   Kovacic, Vedran ^a   Radic, Josipa ^a   Ljutic, Dragan ^a   Jelicic, Ivo ^a  

^a UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Cognition disorders; Dementia; Elderly; Enoxaparin sodium; Haemodialysis; Low molecular weight heparins; Nadroparin calcium; Parnaparin sodium

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PARNAPARIN;

AGE; AGED; ALZHEIMER DISEASE; ANEMIA; BRAIN CIRCULATION; BRAIN EDEMA; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; EDUCATIONAL STATUS; ETHNICITY; GENDER; GERIATRIC PATIENT; HEAD INJURY; HEMOCONCENTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERVISCOSITY SYNDROME; HYPOTENSION; INDEPENDENCE; KIDNEY TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MICROVASCULATURE; MULTIINFARCT DEMENTIA; OBESITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUALITY OF LIFE; RACE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOSIS; VASCULAR COGNITIVE DEFECT; VASODILATATION;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA, VASCULAR; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RENAL DIALYSIS;

EID: 84255191012     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11592870-000000000-00000     Document Type: Review

References (58)

1. Madero M, Gul A, Sarnak MJ. Cognitive function in chronic kidney disease. Semin Dial 2008; 21: 29-37
2. Wright S. Chapter 20. Hemodialysis in elderly patients. In: Geriatric nephrology curriculum. Washington, DC: American Society of Nephrology, 2009 [online]. Available from URL: http://www.asn-online.org/education-and-meetings/ geriatrics/ OnlineGeriatricsCurriculum.pdf [Accessed 2011 Sep 11]
3. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease population: an occult burden. Adv Chronic Kidney Dis 2008; 15 (2): 123-32 (Pubitemid 351343871)
4. Agganis BT, Weiner DE, Giang LM, et al. Depression and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis 2010; 56 (4): 704-12
5. Onyike CU. Cerebrovascular disease and dementia. Int Rev Psychiatry 2006; 18 (5): 423-31 (Pubitemid 44691442)
6. Pereira A, Weiner DE, Scott T, et al. Subcortical cognitive impairment in dialysis patients.Hemodial Int 2007; 11: 309-14 (Pubitemid 46958584)
7. Selnes OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol 2006; 2 (10): 538-47 (Pubitemid 44445810)
8. Saele K, Søonnesyn H, Aarsland D, et al. Cognitive failure in terminal kidney disease. Tidsskr Nor Laegeforen 2009; 129 (4): 296-9
9. Griva K, Stygall J, Hankins M, et al. Cognitive impairment in 7-years mortality in dialysis patients. Am J Kidney Dis 2010; 56 (4): 693-703
10. Knopman DS, Boeve BF, Peterson RC. Essentials of the proper diagnoses in mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc 2003; 78: 1290-308 (Pubitemid 37193520)
11. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 2006; 3 (2): 161-70
12. Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int 2011; 79: 14-22
13. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis 2008; 101: 181-9 (Pubitemid 351739263)
14. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimers disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimers Association, and the American Geriatric Society. JAMA 1997; 278: 1363-71 (Pubitemid 27449698)
15. Fukunishi I, Kitaoka T, Shirai T, et al. Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron 2002; 91: 344-7 (Pubitemid 34621709)
16. OBrien JT. Vascular cognitive impairment. Am J Geriatr Psychiatry 2006; 14 (9): 724-33
17. Purandare N, Oude Voshaar RC, Burns A, et al. Paradoxical embolization: a potential cause of cerebral damage in Alzheimers disease? Neurol Res 2006; 28 (6): 679-84 (Pubitemid 44433329)
18. Roman GC. Facts, myths, and controversies in vascular dementia. J Neurol Sci 2004; 226: 49-52 (Pubitemid 39505405)
19. Posner HB, Tang MX, Luchsinger J, et al. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002; 58: 1175-81 (Pubitemid 34411860)
20. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimers disease and decline in cognitive function. Arch Neurol 2004; 61: 661-6 (Pubitemid 38637681)
21. Murray AM, Pederson SL, Tupper DE, et al. Acute variation in cognitive function in hemodialysis patients: a cohort study with repeated measures. Am J Kidney Dis 2007; 50: 270-8 (Pubitemid 47095078)
22. Kovacic V, Ljutic D, Dodig J, et al. Influence of haemodialysis on early markers of atherosclerosis. Nephrology 2008; 13: 472-9
23. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimers disease: inflammation, cholesterol, and misfolded protein. Lancet 2004; 363: 1139-46
24. Lindqvist R, Carlsson M, Sjoden PO. Coping strategies and health-related quality of life among spouses of continuous ambulatory peritoneal dialysis, haemodialysis, and transplant patients. J Adv Nurs 2000; 31: 1398-408
25. Radic J, Ljutic D, Radic M, et al. The possible impact of dialysis modality on cognitive function in chronic dialysis patients. Neth J Med 2010; 68 (4): 11-5
26. Kimmel PL, Levy NB. Psychology and rehabilitation. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of dialysis. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 413-9
27. Kurella Tamura M, Larive B, Unruh M, et al. Prevalence and correlates of cognitive impairment in the frequent hemodialysis network (FHN) trials. Clin J Am Nephrol 2010; 8: 1429-38
28. Stefanidis I, Bach R, Mertens PR, et al. Influence of hemodialysis on the mean blood flow velocity in the middle cerebral artery. Clin Nephrol 2005; 64: 129-37 (Pubitemid 41079009)
29. Prohovnik I, Post J, Uribarri J, et al. Cerebrovascular effects of hemodialysis in chronic kidney disease. J Cereb Blood Flow Metab 2007; 27: 1861-9 (Pubitemid 47624545)
30. Mizumasa T, Hirakata H, Yoshimitsu T, et al. Dialysisrelated hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients: a 3-year prospective study. Nephron Clin Pract 2004; 97: c23-30 (Pubitemid 38721045)
31. Longstreth Jr W, Larsen EK, Klein R, et al. Associations between findings on cranial magnetic resonance imaging and retinal photography in the elderly: the Cardiovascular Health Study. Am J Epidemiol 2007; 165: 78-84 (Pubitemid 46026212)
32. Haile M, Galoyan S, Li Y-S, et al. Nimodipine-induced hypotension but not nitroglycerin-induced hypotension preserves long-term memory [abstract]. J Neurosurg Anesthesiol 2010; 22 (4): 433
33. de la Torre JC. How do heart disease and stroke become risk factors for Alzheimers disease? Neurol Res 2006; 28 (6): 637-44 (Pubitemid 44433323)
34. Moretti R, Torre P, Antonello RM, et al. Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag 2008; 4 (2): 395-402 (Pubitemid 351711967)
35. Protogeroy AD, Safar ME, Iaria P, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 2007; 50: 172-87
36. Zager PG, Nikolic J, Brown RH, et al. U curve association of blood pressure and mortality in hemodialysed patients. Medical Directors of Dialysis Clinics Inc. Kidney Int 1998; 54: 561-9 (Pubitemid 28357420)
37. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Pre-dialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. AmJ Kidney Dis 1999; 33: 507-17
38. Sadowski M, Pankiewicz J, Scholtzova H, et al. Links between the pathology of Alzheimers disease and vascular dementia. Neurochem Res 2004; 29 (6): 1257-66 (Pubitemid 39023498)
39. Pankiewicz J, Scholtzova H, Sadowski M, et al. Global ischemia exacerbates Alzheimers disease related pathology in transgenic mice [abstract no. 534. 7-S583]. Society for Neuroscience Abstract Viewer and Itinerary Planner 2003; 7 Suppl. 5
40. Alves TC, Busatto GF. Regional cerebral blood flow reductions, heart failure and Alzheimers disease. Neurol Res 2006; 28 (6): 579-87 (Pubitemid 44433316)
41. Birkenhager WH, Staessen JA. Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog Cardiovasc Dis 2006; 49 (1): 1-10 (Pubitemid 44080799)
42. Davenport A. Intradialytic complications during hemodialysis. Hemodial Int 2006; 10: 162-7
43. Hata R, Matsumoto M, Handa N, et al. Effects of hemodialysis on cerebral circulation evaluated by transcranial Doppler ultrasonography. Stroke 1994; 25: 408-12 (Pubitemid 24047269)
44. Stafie ME, Checherita IA, Niculae A, et al. Intradialytic hypotension: mechanisms and therapeutic implications. Ther Pharmacol Clin Toxicol 2010; 14 (1): 57-62
45. Radic J, Ljutic D, Kovacic V, et al. Blood pressure variability during haemodialysis session impaired cognitive and motor functions in uremic patients [abstract]. J Hypertens 2010; 28: pe149
46. Gelb S, Shapiro RJ, Hill A, et al. Cognitive outcome following kidney transplantation. Nephrol Dial Transplant 2008; 23: 1032-8 (Pubitemid 351767548)
47. Tangphao O, Chalon S, Heitor J, et al. Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther 1999; 66: 232-8 (Pubitemid 29451754)
48. Sain M, Ljutic D, Radic J, et al. Decreasing of nadroparin doses have influence on blood pressure in haemodialysed patients [abstract]. J Hypertens 2009; 27 (4): S40-1
49. Arici M, Altun B, Dinler O, et al. Haemodialysis hypotension and nitric oxide production: comparison of heparin with parnaparin. Blood Purif 2002; 20: 145-9 (Pubitemid 34701968)
50. Bergamaschini L, Donarini C, Gobbo G, et al. Activation of complement and contact system in Alzheimers disease. Mech Ageing Dev 2001; 122: 1971-83 (Pubitemid 32925107)
51. Arnaud L, Robakis NK, Figueiredo-Pereira ME. It may take inflammation, phosphorylation and ubiquitination to tangle in Alzheimers disease. Neurodegener Dis 2006; 3 (6): 313-9 (Pubitemid 46034207)
52. Farkas I, Takahashi M, Fukuda A, et al. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimers disease. J Immunol 2003; 170: 5764-71 (Pubitemid 36617870)
53. Bergamaschini L, Rossi E, Storini C, et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and b-amyloid accumulation in mouse model of Alzheimers disease. J Neurosci 2004; 24 (17): 4181-6 (Pubitemid 38620793)
54. Matsuoka Y, Saito M, LaFrancois J, et al. Novel therapeutic approach for the treatment of Alzheimers disease by peripheral administration of agents with the affinity to b-amyloid. J Neurosci 2003; 23: 29-33 (Pubitemid 36050401)
55. Bergamaschini L, Donarini C, Rossi E, et al. Heparin attenuate cytotoxic and inflammatory activity of Alzheimer amyloid beta in vitro. Neurobiol Aging 2002; 23: 531-6 (Pubitemid 34495463)
56. Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 2003; 15 (1): 11-8 (Pubitemid 37376350)
57. Zhu H, Yu J, Kindy MS. Inhibition of amyloidosis using low molecular weight heparins. Mol Med 2001; 7: 517-22 (Pubitemid 33701957)
58. Kourtzelis I, Markiewski MM, Doumas M, et al. Complement anaphylatoxin C5a contributes to hemodialysisassociated thrombosis. Blood 2010; 116 (4): 631-9